Published July 27, 2023 | Version v1
Journal article Open

In Silico docking studies on thrombolytic properties of Homoeopathic Medicine Crataegus oxycantha by activation of tissue-Plasminogen Activator in the treatment of Vascular Thrombosis

Creators

Description

ABSTRACT: The main aim of this study is to analyse the effective thrombolytic activity of Homoeopathic Medicine Crataegus oxyacantha in the treatment of Vascular Thrombosis. A thrombus may form if a vein or an artery or surrounding tissue is damaged. The thrombi can affect the flow of blood through arteries or veins and if the thrombi gets detached from the endothelium of the blood vessel, it lodges in vital organs such as the brain, heart, and lungs, which pose a serious threat (Lyaker et al., 2013)[13]. Plasminogen activation is a key event in the fibrinolytic system that results in blood clot dissolution and promotes cell migration and tissue remodelling. In this study, a total of 4 phytochemical constituents from Crataegus oxycantha were selected for docking studies. Crataegolic acid, Epicatechin, and Vitexin showed significant binding against the target plasminogen. The present work was carried out on computer-aided molecular modelling and the strength of the ligand was validated using binding energy. The bioactive compounds like Epicatechin and Vitexin exhibited good dock scores and these phytochemical constituents of Crataegus oxycantha may exert promising thrombolytic activity. Further in vivo study and RCT are required to validate the thrombolytic activity of Homoeopathic Medicine Crataegus oxycantha.

Files

Crategus VHMC Sapere Issue 2.pdf

Files (7.9 MB)

Name Size Download all
md5:7863fe96af7d34671d05e652e5cb9529
7.9 MB Preview Download

Additional details

References

  • Alshehri B, Vijayakumar R, Senthilkumar S, Ismail A, Abdelhadi A, Choudhary RK, et al. Molecular target prediction and docking of anti-thrombosis compounds and its activation on tissue-plasminogen activator to treat stroke. Journal of King Saud University - Science. 2022 Jan;34(1):101732
  • Amiri M, Jalali-Javaran M, Haddad R, Ehsani P. In silico and in vivo analyses of the mutated human tissue plasminogen activator (mtPA) and the antithetical effects of P19 silencing suppressor on its expression in two Nicotiana species. Sci Rep. 2018 Sep 19;8(1):14079
  • Bikadi Z, Hazai E. Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of AutoDock. J Cheminform. 2009 Dec;1(1):15
  • Boericke W. New manual of homoeopathic materia medica and repertory: including Indian drugs, nosodes, uncommon remedies, relationship, sides of the body & drug affinities. Augmented ed., based on 9th ed., reprint ed. New Delhi: B. Jain Publishers; 2005
  • Dudley JT, Deshpande T, Butte AJ. Exploiting drug-disease relationships for computational drug repositioning. Briefings in Bioinformatics. 2011 Jul 1;12(4):303–11
  • Elokely KM, Doerksen RJ. Docking Challenge: Protein Sampling and Molecular Docking Performance. J Chem Inf Model. 2013 Aug 26;53(8):1934–45
  • García-Godoy M, López-Camacho E, García-Nieto J, Nebro A, Aldana-Montes J. Solving Molecular Docking Problems with Multi-Objective Metaheuristics. Molecules. 2015 Jun 2;20(6):10154–83
  • Glaab E. Building a virtual ligand screening pipeline using free software: a survey. Brief Bioinform. 2016 Mar;17(2):352–66
  • Halgren TA. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem. 1996 Apr;17(5–6):490–519
  • Heit JA. Thrombophilia. In: Consultative Hemostasis and Thrombosis [Internet]. Elsevier; 2013 [cited 2023 Feb 5]. p. 205–39. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9781455722969000142
  • Jorgensen WL. The Many Roles of Computation in Drug Discovery. Science. 2004 Mar 19;303(5665):1813–8
  • Katz JM, Tadi P. Physiology, Plasminogen Activation. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2023 Feb 5]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK539745/
  • Lyaker M, Tulman D, Dimitrova G, Pin R, Papadimos T. Arterial embolism. Int J Crit Illn Inj Sci. 2013;3(1):77
  • Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem. 1998 Nov 15;19(14):1639–62
  • Nicolini FA, Nichols WW, Mehta JL, Saldeen TGP, Schofield R, Ross M, et al. Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator. Journal of the American College of Cardiology. 1992 Jul;20(1):228–35
  • Parry MAA, Zhang XC, Bode W. Molecular mechanisms of plasminogen activation: bacterial cofactors provide clues. Trends in Biochemical Sciences. 2000 Feb;25(2):53–9
  • Schenone M, Dančík V, Wagner BK, Clemons PA. Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol. 2013 Apr;9(4):232–40
  • Sembulingam K, Sembulingam P. Essentials of medical physiology. Sixth edition. New Delhi: Jaypee Brothers Medical Publishers; 2013
  • Solis FJ, Wets RJB. Minimization by Random Search Techniques. Mathematics of OR. 1981 Feb;6(1):19–30
  • Thomford N, Senthebane D, Rowe A, Munro D, Seele P, Maroyi A, et al. Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery. IJMS. 2018 May 25;19(6):1578
  • Ursu O, Rayan A, Goldblum A, Oprea TI. Understanding drug‐likeness. WIREs Comput Mol Sci. 2011 Sep;1(5):760–81
  • Wang J, Xiong X, Feng B. Effect of Crataegus Usage in Cardiovascular Disease Prevention: An Evidence-Based Approach. Evidence-Based Complementary and Alternative Medicine. 2013;2013:1–16